In summary, our findings demonstrate that baseline steroid use, particularly at high doses, decreases the efficacy of ICI therapy for patients with NSCLC and correlates with decreased PB CX3CR1+ CD8+ T cells. The gene discussed is CX3CR1; the disease is non-small cell lung carcinoma.